Compare NTCT & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTCT | GENB |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 1999 | N/A |
| Metric | NTCT | GENB |
|---|---|---|
| Price | $38.48 | $15.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $31.00 | $23.20 |
| AVG Volume (30 Days) | ★ 484.0K | 287.8K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $891,820,000.00 | N/A |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | $2.55 | $16.58 |
| P/E Ratio | $36.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.40 | $11.00 |
| 52 Week High | $40.92 | $16.75 |
| Indicator | NTCT | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 63.75 | 63.72 |
| Support Level | $26.16 | $11.52 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.29 | 1.18 |
| MACD | 0.31 | 0.23 |
| Stochastic Oscillator | 71.58 | 82.66 |
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.